多瑞医药：王庆太、曹晓兵要约收购期满 股票复牌

Group 1 - The core point of the article is that Duori Pharmaceutical (301075.SZ) announced the completion of the acquisition offer by Wang Qingtai and Cao Xiaobing, with the acquirers and their concerted parties holding a total of 43.12 million shares, accounting for 53.90% of the total share capital [2] - The company's equity distribution still meets the listing conditions after the acquisition [2] - The company's stock will resume trading on February 27, 2026 [2]